MX2012014928A - Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma. - Google Patents
Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma.Info
- Publication number
- MX2012014928A MX2012014928A MX2012014928A MX2012014928A MX2012014928A MX 2012014928 A MX2012014928 A MX 2012014928A MX 2012014928 A MX2012014928 A MX 2012014928A MX 2012014928 A MX2012014928 A MX 2012014928A MX 2012014928 A MX2012014928 A MX 2012014928A
- Authority
- MX
- Mexico
- Prior art keywords
- high density
- lipid
- density lipoprotein
- formulation
- production method
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Una formulación de lipoproteína de alta densidad reconstituida teniendo toxicidad relativamente baja comprende una apolipoproteína tal como ApoAl o fragmento de la misma, un lípido y un detergente a un nivel que es aproximadamente 5-50% de aqué que normalmente causaría toxidad al hígado al administrar a un humano. El lípido es óptimamente fosfatidilcolina a aproximadamente 30-50 g/L y la relación molar de apolipoproteína:lípido está óptimamente en el rango de 1:40 a 1:75. La formulación es útil para tratar enfermedades o condiciones tales como enfermedad cardiovascular, hipercolesterolemia e hipocolesterolemia inclusive de síndrome coronario agudo (ACS), aterosclerosis e infarto al miocardio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35992510P | 2010-06-30 | 2010-06-30 | |
| PCT/AU2011/000819 WO2012000048A1 (en) | 2010-06-30 | 2011-06-30 | A reconstituted high density lipoprotein formulation and production method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012014928A true MX2012014928A (es) | 2013-03-22 |
Family
ID=45401226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012014928A MX2012014928A (es) | 2010-06-30 | 2011-06-30 | Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma. |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8999920B2 (es) |
| EP (3) | EP2588113B1 (es) |
| JP (2) | JP5989641B2 (es) |
| KR (1) | KR101782309B1 (es) |
| CN (2) | CN105396122B (es) |
| AU (1) | AU2011274238B2 (es) |
| CA (1) | CA2803031C (es) |
| DK (2) | DK3178481T3 (es) |
| ES (2) | ES2718234T3 (es) |
| HU (2) | HUE042391T2 (es) |
| IL (1) | IL223815A (es) |
| MX (1) | MX2012014928A (es) |
| PL (2) | PL3178481T3 (es) |
| SG (1) | SG186386A1 (es) |
| TR (1) | TR201903209T4 (es) |
| TW (1) | TWI531388B (es) |
| WO (1) | WO2012000048A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201903209T4 (tr) | 2010-06-30 | 2019-03-21 | Csl Ltd | Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi. |
| US9125943B2 (en) * | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
| CN103833840A (zh) * | 2012-11-27 | 2014-06-04 | 上海复星医药（集团）股份有限公司 | 一种从人血浆中提取高密度脂蛋白及分离纯化载脂蛋白apoA-I的方法 |
| SG11201509565VA (en) * | 2013-06-05 | 2015-12-30 | Csl Ltd | Process for preparing apolipoprotein a-i (apo a-i) |
| KR102437202B1 (ko) * | 2013-08-08 | 2022-08-29 | 시에스엘 리미티드 | 오염 제거 방법 |
| EP2853259A1 (en) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| KR101563403B1 (ko) * | 2013-11-05 | 2015-10-26 | 영남대학교 산학협력단 | 지방물질의 안전성 평가방법 |
| SG11201609084QA (en) | 2014-05-02 | 2016-11-29 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| WO2016104690A1 (ja) * | 2014-12-25 | 2016-06-30 | 国立大学法人京都大学 | 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー |
| CA3032229A1 (en) | 2016-07-27 | 2018-02-01 | Hartis-Pharma Sa | Therapeutic combinations to treat red blood cell disorders |
| KR20190084095A (ko) * | 2016-11-10 | 2019-07-15 | 시에스엘 리미티드 | 심근경색의 재구성된 고밀도 지질단백질 치료 |
| US20200261549A1 (en) * | 2017-11-07 | 2020-08-20 | Alphacore Pharma Llc | Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms |
| WO2019133358A2 (en) * | 2017-12-28 | 2019-07-04 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
| CN112546201A (zh) * | 2019-09-26 | 2021-03-26 | 中国科学院生物物理研究所 | 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用 |
| KR102531293B1 (ko) * | 2021-12-06 | 2023-05-16 | (주) 멥스젠 | 신규한 재구축 고밀도 지단백 나노입자 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1335077C (en) | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
| US5652339A (en) * | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| CN1283313C (zh) | 2001-09-28 | 2006-11-08 | 埃斯佩里安医疗公司 | α螺旋状载脂蛋白或HDL关联蛋白在制备局部给药预防和治疗再狭窄的药物中的用途 |
| US20040067873A1 (en) | 2002-05-17 | 2004-04-08 | Dasseux Jean-Louis H. | Method of treating dyslipidemic disorders |
| US20040038891A1 (en) | 2002-05-17 | 2004-02-26 | Bisgaier Charles L. | Methods and compositions for the treatment of ischemic reperfusion |
| PE20050438A1 (es) | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| US20070254832A1 (en) | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
| CN100586958C (zh) * | 2006-12-20 | 2010-02-03 | 上海莱士血液制品股份有限公司 | 高纯度载脂蛋白a-i的制备方法 |
| KR100992488B1 (ko) | 2006-12-29 | 2010-11-05 | 주식회사 녹십자 | ＡｐｏＡ-Ｉ의 정제방법 및 정제된ＡｐｏＡ-Ｉ을 이용한재구축 ＨＤＬ의 생산 방법 |
| SG183743A1 (en) | 2007-08-17 | 2012-09-27 | Csl Behring Gmbh | Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i |
| WO2010057203A2 (en) * | 2008-11-17 | 2010-05-20 | The Board Of Regents Of The University Of Texas System | Hdl particles for delivery of nucleic acids |
| TR201903209T4 (tr) | 2010-06-30 | 2019-03-21 | Csl Ltd | Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi. |
| DK2767546T3 (en) | 2011-02-07 | 2019-02-04 | Cerenis Therapeutics Holding Sa | Lipoprotein complexes and their preparation and uses |
| US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
-
2011
- 2011-06-30 TR TR2019/03209T patent/TR201903209T4/tr unknown
- 2011-06-30 EP EP11799979.7A patent/EP2588113B1/en active Active
- 2011-06-30 WO PCT/AU2011/000819 patent/WO2012000048A1/en active Application Filing
- 2011-06-30 US US13/805,488 patent/US8999920B2/en active Active
- 2011-06-30 MX MX2012014928A patent/MX2012014928A/es active IP Right Grant
- 2011-06-30 PL PL16203579T patent/PL3178481T3/pl unknown
- 2011-06-30 JP JP2013516907A patent/JP5989641B2/ja active Active
- 2011-06-30 ES ES16203579T patent/ES2718234T3/es active Active
- 2011-06-30 HU HUE16203579A patent/HUE042391T2/hu unknown
- 2011-06-30 EP EP18215066.4A patent/EP3492085A1/en active Pending
- 2011-06-30 DK DK16203579.4T patent/DK3178481T3/en active
- 2011-06-30 EP EP16203579.4A patent/EP3178481B1/en active Active
- 2011-06-30 CN CN201510593566.4A patent/CN105396122B/zh active Active
- 2011-06-30 TW TW100123185A patent/TWI531388B/zh active
- 2011-06-30 KR KR1020137002377A patent/KR101782309B1/ko active IP Right Grant
- 2011-06-30 AU AU2011274238A patent/AU2011274238B2/en active Active
- 2011-06-30 HU HUE11799979A patent/HUE032560T2/en unknown
- 2011-06-30 SG SG2012093076A patent/SG186386A1/en unknown
- 2011-06-30 DK DK11799979.7T patent/DK2588113T3/en active
- 2011-06-30 ES ES11799979.7T patent/ES2617977T3/es active Active
- 2011-06-30 PL PL11799979T patent/PL2588113T3/pl unknown
- 2011-06-30 CA CA2803031A patent/CA2803031C/en active Active
- 2011-06-30 CN CN201180036314.1A patent/CN103118683B/zh active Active
-
2012
- 2012-12-23 IL IL223815A patent/IL223815A/en active IP Right Grant
-
2015
- 2015-02-27 US US14/633,880 patent/US9439946B2/en active Active
-
2016
- 2016-06-02 JP JP2016110551A patent/JP2016188226A/ja active Pending
- 2016-08-19 US US15/241,895 patent/US10335457B2/en active Active
-
2019
- 2019-06-19 US US16/445,937 patent/US11058747B2/en active Active
-
2021
- 2021-07-06 US US17/368,464 patent/US11723953B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012014928A (es) | Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma. | |
| CY1123945T1 (el) | Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες | |
| NZ727849A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| EA200700924A1 (ru) | Соединения ряда дибензиламина и их производные | |
| CL2012001124A1 (es) | Composición farmacéutica que comprende un extracto terapéutico concentrado, que comprende fosfolípidos en concentración de 60 a 99% y uso para tratar enfermedades cardiovasculares, reducir niveles de triglicérido, reducir colesterol ldl y aumentar colesterol hdl. | |
| EA201070187A1 (ru) | Модифицированные ферменты лецитин-холестерин ацилтрансферазы | |
| MX2018012161A (es) | Lipidos y composiciones novedosas para el suministro de terapeuticos. | |
| WO2009055568A3 (en) | Liposomal vancomycin formulations | |
| BG105429A (en) | 4-amino-substituted-2-substituted-1,2,3,4- tetrahydroquinolines as cetp inhibitors | |
| MX2010009235A (es) | Estructuras fibrosas. | |
| NZ602557A (en) | Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | |
| NZ603332A (en) | Sweet flavor modifier | |
| MX2013010076A (es) | Composiciones y metodos que comprenden c16:1n7 palmitoleato. | |
| WO2013022922A3 (en) | Fibrous structures | |
| TW200736235A (en) | Dibenzyl amine compounds and derivatives | |
| MA34286B1 (fr) | Compositions pharmaceutiques et procédés pour les fabriquer | |
| WO2005092929A8 (en) | Hyaluronic acid butyric esters with a low degree of substitution, procedure for their preparation and use | |
| NZ631131A (en) | Reconstituted hdl formulation | |
| WO2012119781A3 (en) | Novel lipids, phospholipids, phospholipid and lipid compositions and their use | |
| UA108835C2 (uk) | Спосіб отримання суміші похідних лактиду | |
| MX2013002145A (es) | Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma. | |
| EA200970377A1 (ru) | Композиции фенилалкиламинокарбамата | |
| JP2015535263A5 (es) | ||
| ATE528990T1 (de) | Desinfektions- und entkeimungsmittel | |
| EA201390659A1 (ru) | Способы лечения с применением липидных соединений |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |